The study will evaluate the safety and tolerability of ACE-536 in beta-thalassemia intermedia patients with anemia and the ability of ACE-536 to generate an erythroid response in these patients. Eligible patients may have received up to 6 red blood cell transfusions during the previous 12 months (with none during the 8-week period prior to study enrollment). An erythroid response in this study is defined as an increase in hemoglobin of at least 1.5 g/dL from pretreatment baseline values, sustained for at least 14 days, in the absence of a red blood cell transfusion. The expected starts in December 2012 and the expected completion date is November 2014.

More information: clinicaltrials.gov, ITHANET Clinical Trials